We speak to infectious diseases specialist, Ellie Goldstein (Santa Monica, CA, USA), about his recent publication on real world data and the challenges facing drug-resistant infections.
Another big pharmaceutical is retreating from the development of new antibiotics, highlighting concerns around the challenges facing this market.
Changes in both antibiotic concentration and nutrient availability can push populations beyond a tipping point, creating irreversible shifts in community composition to drug-resistance.
Small-molecule compounds designed to tag the cell surface of Gram-negative bacteria and trigger an immunological response have shown promise.
Antibiotic effectiveness can be restored if utilized in the correct combination with each other, non-antibiotic adjuvants or even food additives.
The US FDA has approved Zemdri for use in adults with complicated urinary tract infections; however, the agency has also issued a response for bloodstream infections noting there isn’t substantial evidence of Zemdri’s effectiveness.
Researchers have discovered a high prevalence of colistin-resistant E. coli in the Vietnamese town of Nguyen Xa, according to research presented at ASM Microbe.
An isolate of colistin-heteroresistant, carbapenem-resistant, hypervirulent/hypermucoviscous Klebsiella pneumoniae has been identified in the USA.
In research presented at ASM Microbe a team have delved into the dynamics of E. coli in urban streams in the USA, indicating possible antibiotic resistance activity.
A study presented at ASCO this weekend has suggested that antibiotic use greatly reduces the progression-free survival and overall survival of cancer patients receiving immunotherapy.
